E3 ligase Ligand 10 is primarily utilized in the field of targeted protein degradation, a cutting-edge approach in drug discovery and therapeutic development. It serves as a key component in the design of PROTACs (Proteolysis Targeting Chimeras), which are bifunctional molecules that recruit E3 ubiquitin ligases to specific target proteins. By facilitating the ubiquitination and subsequent degradation of disease-causing proteins, this ligand plays a crucial role in addressing challenging therapeutic targets, such as those implicated in cancer, neurodegenerative diseases, and other disorders. Its application enables the selective elimination of proteins that are traditionally considered "undruggable," offering a novel strategy for developing effective treatments. Additionally, it is used in research to study protein function and validate targets in biological pathways, contributing to advancements in molecular biology and pharmacology.